nrg1 fusion-driven tumors: biology, detection, and role of afatinib and other erbb-targeting agents
Published 1 year ago • 1.6K plays • Length 12:49Download video MP4
Download video MP3
Similar videos
-
8:47
study of 693 nsclc patients treated with afatinib
-
1:18
dr. tolba on targeting nrg1 fusions with afatinib
-
2:09
dr. tolba on targeting nrg1 fusions in nsclc
-
4:03
phase i/ii trial of zenocutuzumab for tumors with nrg1 fusions
-
11:53
insight 2: a phase ii study of tepotinib plus osimertinib in met-amplified nsclc
-
5:04
gefitinib: inhibitor of egfr tyrosine kinase mutants in nsclc
-
5:12
brain derived neurotrophic factor
-
35:40
why do you keep getting inflamed?
-
9:27
post-hoc analysis of sequential afatinib and osimertinib in nsclc patients
-
1:59
dr. tolba on the use of afatinib in nrg1-mutated lung adenocarcinoma
-
9:16
behind the mystery: nrg1 fusions
-
17:27
how, when, and where to utilize erlotinib, afatinib, and gefitinib in egfr positive nsclc
-
2:45
dr. liu on nrg1 fusions in oncology
-
14:30
the detection of ntrk gene fusions in nsclc
-
4:27
entrectinib: a review in ntrk solid tumours and ros1 nsclc
-
1:35
afatinib for advanced egfrm-positive nsclc
-
6:28
sequential treatment with afatinib and osimertinib in patients with egfr mutation-positive nsclc
-
16:22
debate: drug of choice for exon 19 del egfr mutant nsclc - afatinib
-
2:05
alta-1l: brigatinib vs crizotinib in nsclc
-
2:31
dr. duruisseaux on the incidence of nrg1 fusions in solid tumors
-
1:14
dr. trombetta on recurrent nrg1 rearrangements in invasive mucinous adenocarcinoma
-
2:18
alta-1l: brigatinib is superior to crizotinib in alk nsclc